$MATN UPDATE: GOOD!!! AGOURA HILLS, Calif., March 25, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc.(MATN) (“Mateon”) dedicated to the development of OT-101, a TGF-Beta antisense drug candidate, today provided an update on its rapid antiviral response program targeting coronaviruses, initially targeting COVID-19. OT-101 continued to show significant activity against coronaviruses and in the new testing results, two additional therapeutic oligonucleotides designed to target COVID-19 also demonstrated potent anti-viral activity. Contact Information: For Mateon Therapeutics, Inc.(MATN): Amit Shah Email: ashah@oncotelic.com Image: Oncotelic Logo.png Source: Mateon Therapeutics(MATN)
  • 3